CLSD Clearside Biomedical, Inc.

7.50
-0.04  -1%
Previous Close 7.54
Open 7.94
Price To book 2.84
Market Cap 189.75M
Shares 25,300,000
Volume 163,725
Short Ratio 3.52
Av. Daily Volume 182,413

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated mid-2017.
Suprachoroidal CLS-TA - TYBEE
Diabetic Macula Edema (DME)
Phase 1/2 enrollment completion announced April 20, 2017. Preliminary data due 2H 2017.
Suprachoroidal CLS-TA - HULK
Diabetic macular edema (DME)
Announced enrollment of the first patient in its Phase 3 trial - February 16, 2017.
Suprachoroidal CLS-TA - SAPPHIRE
Macular edema associated with retinal vein occlusion (RVO)
Phase 3 data preliminary data due early 2018.
Suprachoroidal CLS-TA - PEACHTREE
Macular edema associated with non-infectious uveitis
Phase 1/2 trial to be initiated following IND submission late 2016.
CLS-1002
Wet age-related macular degeneration (Wet-AMD)

Latest News

  1. Surging Earnings Estimates Signal Good News for Clearside (CLSD)
  2. ETFs with exposure to Clearside Biomedical, Inc. : May 15, 2017
  3. Clearside Biomedical, Inc. :CLSD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
  4. Investor Network: Clearside Biomedical, Inc. to Host Earnings Call
  5. Clearside Biomedical, Inc. Announces First Quarter 2017 Financial Results and Provides Corporate Update
  6. Clearside Biomedical, Inc. to Report First Quarter 2017 Financial Results on May 10, 2017 – Conference Call to Follow
  7. Clearside Biomedical, Inc. to Present at the Deutsche Bank 42nd Annual Health Care Conference
  8. Clearside Biomedical, Inc. Announces Completion of Patient Enrollment in Phase 1/2 Open Label Clinical Trial of CLS-TA in Diabetic Macular Edema
  9. Edited Transcript of CLSD earnings conference call or presentation 14-Mar-17 12:30pm GMT
  10. Clearside Biomedical Enters into Strategic Collaboration with EyeKor to Support Clinical Development Efforts
  11. Clearside Biomedical, Inc. to Present at the 16th Annual Needham Healthcare Conference
  12. Clearside Biomedical, Inc. Announces Fourth Quarter And Full Year 2016 Financial Results
  13. Clearside Biomedical, Inc. to Report Fourth Quarter and Full Year 2016 Financial Results on March 14, 2017 – Conference Call to Follow
  14. Clearside Biomedical, Inc. to Present at the Cowen and Company 37th Annual Health Care Conference
  15. Clearside Biomedical, Inc. Receives Notice of Allowance for Ninth U.S. Patent
  16. Clearside Biomedical, Inc. Redirects Pre-Clinical AMD Research Resources Toward Ongoing DME Clinical Development Program